# A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies

> **NCT05688436** · — · RECRUITING · sponsor: **Biogen** · enrollment: 1178 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Diroximel Fumarate
- **BIOLOGICAL:** Alemtuzumab
- **DRUG:** Fingolimod
- **DRUG:** Glatiramer acetate
- **BIOLOGICAL:** Interferon beta
- **BIOLOGICAL:** Natalizumab
- **BIOLOGICAL:** Ocrelizumab
- **BIOLOGICAL:** Ofatumumab
- **DRUG:** Ozanimod
- **BIOLOGICAL:** Peginterferon beta-1a
- **DRUG:** Ponesimod
- **DRUG:** Siponimod

## Key facts

- **NCT ID:** NCT05688436
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-24
- **Primary completion:** 2031-01-17
- **Final completion:** 2031-01-17
- **Target enrollment:** 1178 (ESTIMATED)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05688436

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05688436, "A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05688436. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*